Cortexyme

Cortexyme

Public filings and investment databases show no founding year, no named operators, and no disclosed capital — a blank slate that places it among the least visible firms in the Altss universe. The firm's nominal association with biotech and healthcare services is inferred from sector tagging, but no confirmed portfolio companies, patents, or clinical trials link back to the entity itself. Without a scraped website, LinkedIn presence, or press coverage, Cortexyme's strategy and deployment model remain entirely opaque. No asset-class mix, stage preference, or co-investment activity has been reported. The lack of any named deals or co-investors precludes geographic or sector specificity beyond its California headquarters. Team size, adjacent vehicles like philanthropic foundations or real-asset arms, and any recent operational events are undocumented. The firm has not been involved in any publicly recorded transaction or hiring activity in the last 24 months. The structural differentiator, if any, is the mystery itself: a San Francisco entity with neither a web footprint nor a public investment record may serve as a shell company, a single-family office for an undisclosed individual, or a firm that has dissolved without formal notice. Its classification as a DB entity with no further detail is itself an anomaly worth monitoring.